These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 17678961)

  • 1. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
    Centonze D; Rossi S; Finazzi-Agrò A; Bernardi G; Maccarrone M
    Int Rev Neurobiol; 2007; 82():171-86. PubMed ID: 17678961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.
    Rossi S; Bernardi G; Centonze D
    Exp Neurol; 2010 Jul; 224(1):92-102. PubMed ID: 20353778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.
    Bari M; Rapino C; Mozetic P; Maccarrone M
    Exp Neurol; 2010 Jul; 224(1):74-84. PubMed ID: 20353779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system in targeting inflammatory neurodegenerative diseases.
    Centonze D; Finazzi-Agrò A; Bernardi G; Maccarrone M
    Trends Pharmacol Sci; 2007 Apr; 28(4):180-7. PubMed ID: 17350694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and neurotoxicity.
    Sayre LM; Perry G; Smith MA
    Chem Res Toxicol; 2008 Jan; 21(1):172-88. PubMed ID: 18052107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and the pathogenesis of neurodegenerative disorders.
    Reynolds A; Laurie C; Mosley RL; Gendelman HE
    Int Rev Neurobiol; 2007; 82():297-325. PubMed ID: 17678968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?
    Staines DR
    Med Hypotheses; 2008; 70(2):413-8. PubMed ID: 17582695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].
    Mestre L; Correa F; Docagne F; Clemente D; Ortega-Gutiérrez S; Arévalo-Martín A; Molina-Holgado E; Borrell J; Guaza C
    Rev Neurol; 2006 Nov 1-15; 43(9):541-8. PubMed ID: 17072810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of zinc in ALS.
    Smith AP; Lee NM
    Amyotroph Lateral Scler; 2007 Jun; 8(3):131-43. PubMed ID: 17538774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
    Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
    Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis.
    Correa FG; Mestre L; Docagne F; Borrell J; Guaza C
    Vitam Horm; 2009; 81():207-30. PubMed ID: 19647114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
    Maccarrone M; Battista N; Centonze D
    Prog Neurobiol; 2007 Apr; 81(5-6):349-79. PubMed ID: 17276576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-).
    Liu X; Rush T; Zapata J; Lobner D
    Exp Neurol; 2009 Jun; 217(2):429-33. PubMed ID: 19374900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system.
    Vickers JC; King AE; Woodhouse A; Kirkcaldie MT; Staal JA; McCormack GH; Blizzard CA; Musgrove RE; Mitew S; Liu Y; Chuckowree JA; Bibari O; Dickson TC
    Brain Res Bull; 2009 Oct; 80(4-5):217-23. PubMed ID: 19683034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system and gut-brain signalling.
    Storr MA; Sharkey KA
    Curr Opin Pharmacol; 2007 Dec; 7(6):575-82. PubMed ID: 17904903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
    Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
    Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 18. Microglia in amyotrophic lateral sclerosis.
    Dewil M; Van Den Bosch L; Robberecht W
    Acta Neurol Belg; 2007 Sep; 107(3):63-70. PubMed ID: 18072333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoid-mediated control of synaptic transmission.
    Kano M; Ohno-Shosaku T; Hashimotodani Y; Uchigashima M; Watanabe M
    Physiol Rev; 2009 Jan; 89(1):309-80. PubMed ID: 19126760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
    Pryce G; Baker D
    Handb Exp Pharmacol; 2015; 231():213-31. PubMed ID: 26408162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.